Benjamin Burnett

Stifel initiated coverage on a trio of oncology-focused biotechs Tuesday, recommending buying two and staying sidelined on a third. The Analyst Benjamin Burnett initiated coverage of: bluebird bio Inc NASDAQ: BLUE) with a Hold rating and $109 price target. Iovance Biotherapeutics...

The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. (NASDAQ: NBIX)'s third-quarter results. Given the buoyancy surrounding Ingrezza, analysts scrambled to designate Neurocrine as their top mid-cap pick. Ingrezza...